Recent studies using cloned antigen-specific T lymphocytes and monoclonal antibodies directed at their various surface glycoprotein components have led to identification of the human T-cell-antigen receptor as a surface complex comprised of a clonotypic 90-kilodalton (kDa) Ti heterodimer and the monomorphic 20/25-kDa T3 molecule (1, 2) . Upon binding to the surface of a clone, monoclonal antibodies to either T3 or its associated unique Ti heterodimer induced rapid loss of the T3-Ti complex, a process termed modulation, and inhibited all antigen-specific functions of a given clone. However, at the same time, these antibodies produced a markedly enhanced clonal proliferative response to interleukin 2 (IL-2)-containing media (1) (2) (3) . Moreover, when coupled to the surface of a solid support such as Sepharose, the appropriate surface-linked anti-Ti and anti-T3 antibodies were able to induce IL-2 secretion and clonal proliferation, analogous to physiologic ligand (i.e., antigen) itself (4) . These findings suggested that clonal proliferation resulting from triggering of the T3-Ti antigen receptor might be mediated through the growth factor IL-2. The latter is a 15-kDa sialoglycoprotein that interacts with activated T cells through specific membrane receptors distinct from the T3-Ti complex and is known to induce T-cell growth upon surface binding (5) (6) (7) (8) (9) (10) (11) (12) .
The present study was performed to examine the relationship between the T-cell-antigen receptor and IL-2-mediated T-cell growth.
MATERIALS AND METHODS
Human T-Cell Clones. The human T-cell clones CT8111, CT411, and RW17C were obtained from a single donor's peripheral blood mononuclear cells, cloned, and maintained in culture as described (13, 14) . Briefly, the cytotoxic clones CT8111 and CT411 have a target specificity for class I and class II alloantigens, respectively, both of which are present on the Epstein-Barr virus-transformed human lymphoblastoid B cell line Laz 156 (1, 2, 14, 15) . In contrast, RW17C recognizes ragweed antigen E (RWAGE) in the context of an autologous class II major histocompatibility complex (MHC) gene product. Moreover, RW17C provides potent help for Bcell IgG secretion (16) .
Derivation of Monoclonal Antibodies and Surface Expression of T-Cell Antigens. The clone-specific murine monoclonal antibodies anti-Til, anti-Ti2, and anti-Ti4 and the anti-T3 monoclonal antibodies were obtained from immunizations with individual T-cell clones as described (1, 2, 16, 17) . The antigens defined by the various anti-Ti antibodies appear as clonally unique 90-kDa disulfide heterodimers consisting of 41-43 /3 and 49-53 a chains (anti-Til, clone CT8111; anti-Ti2, clone CT411; and anti-Ti4, clone RW17C) that are associated with the monomorphic T3 structure. These monoclonal antibodies are not crossreactive. Anti-T3, -T4, -T11, and -Ia monoclonal antibodies have been described (18) (19) (20) (21) (22) (23) . Monoclonal antibodies to the IL-2 receptor, termed anti-Tac, and to human IL-2, termed DMS-1, were produced as described (9, 10, 12) .
The reactivity of clonal populations with individual monoclonal antibodies was determined by means of indirect immunofluorescence on an Epics V cell sorter (Coulter) (23) , and the number of binding sites was quantitated by flow cytometry as described (2, 24) . Modulation studies were performed as described (1) .
Purification and Surface Coupling of Monoclonal Antibodies. Anti-Til, anti-Ti2, and anti-Ti4 were individually purified from malignant ascites by using protein A-Sepharose (Pharmacia) (25) . In each case, 5 mg of purified antibody was coupled to 1 
RESULTS
To investigate the molecular basis of enhanced proliferation to IL-2 after T3-Ti modulation, we used three antigen-specific human T-cell clones and a series of anti-clonotypic monoclonal antibodies in conjunction with a homogeneous IL-2 preparation and anti-Tac (9, 10) and DMS-1 (12) by using 125I-labeled monoclonal antibodies (2) . Note that the number of binding sites for anti-Tac on RW17C was considerably lower than the other surface glycoproteins and remained at this level or less as long as the cells were cultured in IL-2-containing media without further antigenic stimulation (see below). In fact, other studies (26) indicate that in the absence of mitogenic or antigenic stimulation, IL-2 receptor expression diminishes on IL-2-dependent T-cell clones over time.
After modulation (Fig. 1, row B ) with anti-Ti4 (or anti-T3 by soluble antibody or antibody coupled to Sepharose beads; data not shown), however, there was a 6-fold increase in the number of IL-2 receptor binding sites as measured by antiTac (62,000). In contrast, anti-Ti4 modulation was associated with a 75% reduction in the number of T3 binding sites (11, 500) , consistent with previous data indicating that the T3 and Ti surface structures are linked to one another in the membrane of human T cells (1, 2) . Unlike T3, the number of T4 molecules remained unaffected by this process, and the T11 surface expression increased by <50%. Given these findings and the above functional data, it would appear that the enhanced in vitro proliferative response to IL-2 by antiTi or anti-T3 modulated T-cell clones is a consequence of the increased density of IL-2 receptors.
Because anti-clonotypic monoclonal antibodies appear to recognize the same antigen binding site as the natural ligand for Ti (4, 16) , it was of interest to determine whether the latter would have similar effects. There was a strong increase in anti-Tac binding sites (61,000 vs. 11,000) and a reduction in T3 surface expression (24,000 vs. 45,000) when RW17C was preincubated with RWAGE and autologous APC (Fig. 1 , row C; Table 2 ). Thus, it appears that this cloned population is fully activated vis-a'-vis IL-2 receptor expression only after antigenic receptor triggering. Note that the number of T3 binding sites (i.e., 24,500) is overestimated by this analysis because the discrete anti-T3 unreactive (T3) T-cell population (Fig. 1, row C) was excluded from the calculation. Although the reason for the bimodal reactivity of anti-T3 on the MHC/antigen-triggered RW17C is not known, it is most likely a consequence of ligand-T3-Ti-receptor binding and cell proliferation.
Perhaps more importantly, Fig. 1 demonstrates that IL-2 receptor expression and T3 modulation were critically dependent on a unique combination of MHC-restricting element and antigen. Thus, a mixture of autologous APC with the irrelevant antigen tetanus toxoid (Fig. 1, row D) or, alternatively, allogeneic APC with the relevant antigen RWAGE (Fig. 1, row E (10, 11) . DISCUSSION To investigate some of the molecular mechanisms underlying T-cell proliferation after triggering of antigen receptors, we utilized three antigen-specific human T-cell clones, CT8111, CT4,1, and RW17C (1, 2, 14, 16) and clonal proliferation analogous to antigen. That the latter response was mediated by IL-2 was evident from the finding that either monoclonal anti-Tac or DMS-1 antibodies blocked clonal proliferation following T3-Ti triggering.
The induction of IL-2 receptors occurred as a discrete event in and of itself and did not appear to require Ti crosslinking (or more precisely, crosslinking of more than two receptors, if one assumes that the antigen receptor is univalent) because it could be mediated by binding of soluble antiTi monoclonal antibody to the clone's surface. In contrast, production and release of IL-2 and subsequent clonal proliferation did not occur in the absence of apparent receptor crosslinking initiated by surface-bound antigen on the stimulator cells or anti-Ti coupled to Sepharose. Note that we cannot formally rule out the possibility that Sepharose-bound antibodies may be acting on these cloned T cells independently of any crosslinking effect, for instance, either by increasing the avidity of the antibody for the receptor or interacting with other surface molecules unrelated to T3-Ti. Such possibilities seem remote because three antibodies to the Ti structure of CT411, regardless of their isotype, have identical functional effect when coupled to Sepharose 4B, and yet none of these soluble anti-Ti antibodies in combination with an uncoupled bead triggers IL-2 release or clonal proliferation (ref. 4 ; data not shown). The identity of the phenotypic changes induced by anti-Ti anti-receptor antibodies and antigen/MHC on RW17C provides further support for the notion that the Ti complex is the receptor for both antigen and MHC.
Therefore, it appears that T-cell proliferation occurs as a series of complex and precisely orchestrated events as outlined in Fig. 2 The present set of findings is in agreement with recent studies with lectin-stimulated peripheral blood T lymphocytes in which it was shown that IL-2 receptor expression occurred during the G1 phase of cell cycle and preceded DNA synthesis (26) . Moreover, the correlation of IL-2 receptor levels with the proportion of cells in active cycle emphasized the importance of antigen receptor triggering on IL-2 responsiveness, especially when IL-2 concentrations become limiting. In addition, induction of IL-2 receptors by antigenic stimulation as shown here provides a rational basis for the empiric observations that IL-2-mediated clonal expansion in vitro is facilitated by repetitive antigenic stimulation. In this regard, recent studies have demonstrated that loss of IL-2 responsiveness is not secondary to down regulation of IL-2 receptors per se but rather secondary to lack of repetitive antigenic challenge (26) .
The view that is emerging regarding the relationship of the T3-Ti antigen receptor to the IL-2 receptor points to a mechanism whereby external stimuli-i.e., antigen-direct the magnitude and extent of T-cell clonal proliferation by means of the IL-2 hormone-receptor system. Immunologic specificity is ensured by the antigen dependence of the IL-2 receptor expression, and yet the reciprocal appearance of T3-Ti and IL-2 receptors presumably leaves the cell in a state of responsiveness to either the hormone or antigen ligand. However, the transient expression of the IL-2 receptors themselves serves as a fail-safe system to eliminate any possibility of uncontrolled growth through an IL-2-dependent mechanism. Whether alteration of this mechanism results in tumor growth in vivo as suggested by studies on continuously growing, IL-2-producing primate tumor lines of T-cell lineage remains to be determined but appears likely (27) .
The present construct clearly implies that T-cell proliferation is mediated through an autocrine network in which antigen-receptor triggering leads to IL-2 receptor expression, IL-2 production, IL-2 release, and subsequent IL-2 receptor occupancy, which ultimately promotes cell division. Note that it does not necessarily follow that all T cells produce and respond to their own IL-2. In fact, one would predict that the failure of certain cells to proliferate to antigen occurs as a consequence of their inability to produce sufficient amounts of endogenous IL-2, although such cells would, in all likelihood, be triggered to express IL-2 receptors. Furthermore, even for IL-2-producing T cells, exogenous sources of IL-2 would amplify clonal proliferation. However, the present results are clearly different than anticipated from the conventional endocrine notion that suggests that one cell type produces IL-2 while a different one responds to it.
The above findings stress the central linkage of the T-cell receptor to the IL-2 hormonal system and the critical role of the latter in T-cell proliferation. The present reagents provide an excellent set of probes with which to evaluate the mechanisms that regulate and maintain physiologic T-cell growth. In addition, they should provide important insights into aberrations of these control mechanisms that could underlie malignant transformation within the T-cell lineage.
